The Food and Drug Administration yesterday approved a new drug application for propofol injectable emulsion, an intravenous general anesthetic and sedation drug in short supply.

“The agency recognizes there is increased demand for certain products, such as propofol injectable emulsion, during the novel coronavirus pandemic, and remains committed to facilitating access to safe and effective medical products to help address critical needs of the American public,” the agency said.

Related News Articles

Headline
The Food and Drug Administration Oct. 15 said it reissued its emergency use authorization for certain, Chinese-manufactured filtering face-piece respirators…
Headline
The Food and Drug Administration Oct. 15 removed epinephrine from the lists of drugs authorized for temporary compounding during the COVID-19 public health…
Headline
The Centers for Medicare & Medicaid Services Oct. 15 said it will incentivize labs to deliver quicker results to patients undergoing COVID-19 diagnostic…
Perspective
Hospitals and health systems have reinvented themselves in many ways to respond to COVID-19. Since March, decades of standard operating procedures have been…
Headline
The National Institutes of Health Oct. 13 announced a study designed to identify promising COVID-19 therapies and investigational drugs that merit larger…
Headline
The Food and Drug Administration Oct. 13 issued and immediately implemented enforcement policy for modifications to FDA-cleared molecular influenza and RSV…